Antibiotic development: A victim of market forces?

IDrugs

Volumn 11, Issue 5, 2008, Pages 340-345

  Tillotson, G S ^a  

^a Replidyne Inc   (United States)

Author keywords

Antibiotic development; Antibiotic resistance; Commercial evaluation; Generic competition

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFDITOREN; CEFTAROLINE FOSAMIL; CEFTOBIPROLE MEDOCARIL; CETHROMYCIN; CIPROFLOXACIN; DALBAVANCIN; FAROPENEM MEDOXOMIL; GATIFLOXACIN; GEMIFLOXACIN; ICLAPRIM; KETOLIDE; LEVOFLOXACIN; MOXIFLOXACIN; NEMONOXACIN; ORITAVANCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; RIFAPENTINE; RX 1741; SULOPENEM; TELAVANCIN; TELITHROMYCIN; TOMOPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC ASPECT; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INFECTION; INVESTMENT; MEDICAL EDUCATION; OTITIS MEDIA; PATENT; PRESCRIPTION; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BIOMEDICAL RESEARCH; DRUG COSTS; DRUG DESIGN; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; HEALTH CARE SECTOR; HUMANS; MODELS, ECONOMIC; TIME FACTORS;

EID: 43549127334     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Guidance for Industry Antibacterial Drug Products: Food and Drug Administration, Rockville, MD, USA (2007). www.fda.gov/cder/guidance/7884dft. pdf
2. Guidance for Industry Acute Bacterial Sinusitis: Food and Drug Administration, Rockville, MD, USA (2007). www.fda.gov/cder/guidance/3895dft. pdf
3. Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N: National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 US faropenem surveillance study. Antimicrob Agents Chemother (2007) 51(12):4382-4389.
4. Tabaee A, Anand VK, Yoon C: Outpatient intravenous antibiotics for methicillin-resistant Staphylococcus aureus sinusitis. Am J Rhinol (2007) 21(2):154-158
5. Perla RJ, Knutson EL, Bellivue PP: Emergence of fluoroquinolone-only resistant Escherichia coli in a community hospital. Clin Infect Dis (2007) 44(9):1255
6. Pichichero ME, Casey JR: Emergence of multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. J Am Med Assoc (2007) 298(15):1772- 1778.
7. Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, Noskin GA, Zembower T: Screening for extended-spectrum β-lactamase-producing Enterobactericeae among high-risk patients, and rates of subsequent bacteremia. Clin Infect Dis (2007) 45(7):846-852.
8. Falagas ME, Fragoulis KN, Karydis I: A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS ONE (2006) 1(1):e11
9. Tillotson GS, Doern GV, Blondeau JM: Optimal antimicrobial therapy: The balance of potency and exposure. Exp Opin Investig Drugs (2006) 15(4):335-337.
10. Low DE, Scheld WM: Strategies for stemming the tide of antimicrobial resistance. J Am Med Assoc (1998) 279(5):394-395.
11. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ et al: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2007) 44(2):159-177.
12. Scalera NM, File TM Jr: How long should we treat community-acquired pneumonia? Curr Opin Infect Dis (2007) 20(2):177-181.
13. Tufts Center for the Study of Drug Development: Tufts University, Boston, MA, USA (2008). csdd.tufts.edu/newsevents/RecentNews.asp
14. Gleason PP, Gunderson BW, Gericke KR: Are incentive-based formularies associated with drug utilization in managed care? Ann Pharmacother (2005) 39(2):339-345.
15. Metlay JP, Powers JH, Dudley MN, Christiansen K, Finch RG: Antimicrobial drug resistance, regulation and research. Emerg Infect Dis (2006) 12(2):183-190.
16. Power E: Impact of antibiotic restrictions: The pharmaceutical perspective. Clin Microbiol Infect (2006)12(Suppl 5):25-34.
17. Bradley JS, Guidos R, Baragona S, Bartlett JG, Rubinstein E, Zhanel GG, Tino MD, Pompliano DL, Tally F, Tipirneni P, Tillotson GS et al: Anti-infective research and development - problems, challenges and solutions. Lancet Infect Dis (2007) 7(1):68-78.
18. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J Jr: The epidemic of antibiotic-resistant infections: A call to action for the medical community from the IDSA. Clin Infect Dis (2008) 46(2):155-164.